The stock of BioTime, Inc. (NYSEMKT:BTX) is a huge mover today! About 232,335 shares traded hands. BioTime, Inc. (NYSEMKT:BTX) has risen 37.68% since March 8, 2016 and is uptrending. It has outperformed by 28.36% the S&P500.
The move comes after 6 months negative chart setup for the $383.46M company. It was reported on Oct, 11 by Barchart.com. We have $3.15 PT which if reached, will make NYSEMKT:BTX worth $53.68M less.
Analysts await BioTime, Inc. (NYSEMKT:BTX) to report earnings on November, 14. They expect $-0.19 earnings per share, down 5.56% or $0.01 from last year’s $-0.18 per share. After $-0.11 actual earnings per share reported by BioTime, Inc. for the previous quarter, Wall Street now forecasts 72.73% negative EPS growth.
According to Zacks Investment Research, “BioTime, Inc. is a clinical-stage biotechnology company focused on developing and commercializing novel therapies in the field of regenerative medicine. The foundation of its core therapeutic technology platform is pluripotent cells that are capable of becoming any of the cell types in the human body. BioTime’s research and other activities have resulted, over time, in the creation of other subsidiaries that address other non-therapeutic market opportunities such as cancer diagnostics, drug development and cell research products, and mobile health software applications.”
Insitutional Activity: The institutional sentiment increased to 2.25 in Q2 2016. Its up 1.29, from 0.96 in 2016Q1. The ratio is positive, as 3 funds sold all BioTime, Inc. shares owned while 13 reduced positions. 9 funds bought stakes while 27 increased positions. They now own 38.13 million shares or 10.80% more from 34.42 million shares in 2016Q1.
Swiss Bancorp has invested 0% of its portfolio in BioTime, Inc. (NYSEMKT:BTX). Moreover, Douglass Winthrop Advsr Ltd Liability Corp has 0% invested in BioTime, Inc. (NYSEMKT:BTX) for 15,000 shares. Blackrock Grp Ltd holds 37,580 shares or 0% of its portfolio. Geode Cap Management Ltd Liability Company holds 0% or 370,251 shares in its portfolio. Moreover, Blackrock Inv Mngmt Ltd has 0% invested in BioTime, Inc. (NYSEMKT:BTX) for 232,927 shares. Citigroup has 0% invested in the company for 8,502 shares. Tiaa Cref Invest Management Limited Liability Co holds 0% or 206,408 shares in its portfolio. State Board Of Administration Of Florida Retirement System reported 22,784 shares or 0% of all its holdings. Rhumbline Advisers holds 0% or 48,181 shares in its portfolio. State Street Corporation last reported 886,312 shares in the company. Goldman Sachs Grp Inc Inc Inc accumulated 22,006 shares or 0% of the stock. D E Shaw, a New York-based fund reported 16,615 shares. Nationwide Fund Advsrs has invested 0% of its portfolio in BioTime, Inc. (NYSEMKT:BTX). Manatuck Hill Prtn Limited Liability Company holds 1.01% of its portfolio in BioTime, Inc. (NYSEMKT:BTX) for 880,350 shares. Legal And General Grp Public Ltd last reported 0% of its portfolio in the stock.
More notable recent BioTime, Inc. (NYSEMKT:BTX) news were published by: Businesswire.com which released: “Adjustments Affecting BioTime, Inc. Common Share Purchase Warrants Expiring …” on January 12, 2016, also Businesswire.com with their article: “BioTime, Inc. Announces Proposed Public Offering of Common Stock” published on June 15, 2016, Businesswire.com published: “BioTime, Inc. to Report Second Quarter Results on August 9, 2016” on July 27, 2016. More interesting news about BioTime, Inc. (NYSEMKT:BTX) were released by: Businesswire.com and their article: “BioTime, Inc. Announces the Appointment of Life Sciences Industry Veteran …” published on November 18, 2015 as well as Businesswire.com‘s news article titled: “BioTime, Inc. Reports Third Quarter 2015 Results and Recent Corporate …” with publication date: November 09, 2015.
BTX Company Profile
BioTime, Inc., incorporated on November 30, 1990, is a clinical-stage biotechnology company. The Firm is focused on the field of regenerative medicine, specifically pluripotent stem cell technology. The Firm is engaged in the research and development of therapeutic products for oncology, orthopedics, retinal and neurological diseases and disorders, blood and vascular system diseases and disorders, blood plasma volume expansion, diagnostic products for the early detection of cancer, and hydrogel products that may be used in surgery and products for human embryonic stem cell research. Regenerative medicine refers to therapies based on stem cell technology that are designed to rebuild cell and tissue function lost due to degenerative disease or injury. The Company’s pluripotent stem cell technology is complemented by its HyStem technology for the delivery and engraftment of cells, whether derived from pluripotent stem cells or the patient’s own somatic or adult stem cells, at the desired location.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.